Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer July 28, 2026
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan-Tivozanib Combination for Advanced Kidney Cancer Patients July 28, 2026
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer July 28, 2026
Durable Clinical Activity of Darlifarnib + Cabozantinib Reported in Cabozantinib-Naïve Clear Cell RCC Patients July 28, 2026
FDA Grants Priority Review for TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer July 28, 2026
FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each With Padcev, as Treatment Before and After Surgery for Adults With MIBC July 15, 2026
IND application for HLX3902 approved in China for treatment of metastatic CRPC and solid tumors June 23, 2026
FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each With WELIREG, for Adjuvant Treatment of Certain Patients With Clear Cell RCC June 17, 2026
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares June 17, 2026
Lancet Oncology publishes results of Pivotal Ph 3 Significant DFS Improvement with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer June 10, 2026
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA in Metastatic CRPC June 2, 2026
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Gen Oncology Therapies and $215M Concurrent Private Placement June 2, 2026
FDA Accepts Supplemental BLA for ANKTIVA + BCG in BCG-Unresponsive NMIBC with Papillary Disease; PDUFA Jan 2027 May 26, 2026
HREC Australia approves HLX3902 for Clinical Trial in Australia in metastatic CRPC and other advanced solid tumours May 26, 2026
Positive EU CHMP Opinion for KEYTRUDA + Padcev as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable MIBC May 26, 2026
Ph 2 ARASEC Data Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic CSPC May 21, 2026
Supplemental NDA submitted in Japan for PADCEV + Keytruda in Cisplatin-Eligible Patients with MIBC May 21, 2026
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic HSPC May 21, 2026
